Sichuan Huiyu Pharmaceutical Co.,Ltd. (688553.SH) announced that HYP-6589 tablets (project R&D code: "HY-0006"), a Class 1 innovative drug independently developed by its wholly-owned subsidiary Huiyu Haiyue, is a highly selective SOS1 small molecule inhibitor. Osimertinib (brand name: Tagrisso), a third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor independently developed by AstraZeneca PLC, has already been approved for marketing in China and is indicated for the treatment of specific types of non-small cell lung cancer. Recently, the company's wholly-owned subsidiary, Huiyu Haiyue, signed a Clinical Trial Cooperation Agreement with AstraZeneca to collaborate on clinical combination therapy research involving HYP-6589 tablets and osimertinib. The company's clinical research collaboration with AstraZeneca will see both parties jointly explore combination therapy using the company's self-developed Class 1 innovative chemical drug HYP-6589 tablets and AstraZeneca's osimertinib for specific types of non-small cell lung cancer. The collaborating parties will conduct clinical trial research on the combination of HYP-6589 and osimertinib for treating specific types of non-small cell lung cancer, aiming to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HYP-6589 both as a monotherapy and in combination with osimertinib. The company is committed to fully embracing innovation and accelerating the R&D layout of biological innovative drugs and small molecule innovative drugs in the field of anti-tumor therapy; it currently has 14 Class 1 innovative drug pipelines, involving cutting-edge technology routes such as multi-specific antibodies and antibody-drug conjugates, with 5 of these Class 1 innovative drug pipelines having entered clinical research. This clinical research collaboration with AstraZeneca is beneficial for accelerating the clinical trial process of the company's innovative drugs and enhancing R&D efficiency; it is also conducive to expanding the company's new drug R&D capabilities and scope, saving time and costs associated with the company's new drug clinical trials to a certain extent, and ensuring the smooth progress of the project. This matter is not expected to have a significant impact on the company's financial condition and operating results.
Comments